Roberto Mignone
Known title: DirectorCIK: 0001258394
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Teva Receives FDA Approval for Weltruza, Announces R&D Day. Teva Pharmaceutical Industries secured FDA approval for Weltruza, a once‑monthly long‑acting injectable for schizophrenia. The approval follows the company’s announcement of an R&D day in New York City, where it will discuss its pipeline and future research plans. Barclays raised its price target to $47, citing the new product launch and potential growth in the schizophrenia market. These developments add fresh catalysts to Teva’s outlook.
this person other insiders at TEVA
Transaction History
| GH | ▲ Buy | Option Exercise | 264 | $0 | 9/21/2026 | View on chart |
| TEVA | ▼ Sell | Open Market | 367,600 | $14.4M | 9/18/2026 | View on chart |
| GH | ▲ Buy | Option Exercise | 264 | $0 | 8/21/2026 | View on chart |
| GH | ▲ Buy | Option Exercise | 264 | $0 | 7/21/2026 | View on chart |
| GH | ▲ Buy | Option Exercise | 264 | $0 | 6/21/2026 | View on chart |
| GH | ▲ Buy | Option Exercise | 4,203 | $0 | 6/17/2026 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 14,492 | — | 6/5/2026 | View on chart |
| GH | ▲ Buy | Option Exercise | 264 | $0 | 5/21/2026 | View on chart |
| GH | ▲ Buy | Option Exercise | 264 | $0 | 4/21/2026 | View on chart |
| GH | ▲ Buy | Option Exercise | 264 | $0 | 3/21/2026 | View on chart |
| GH | ▲ Buy | Option Exercise | 264 | $0 | 2/21/2026 | View on chart |
| GH | ▲ Buy | Option Exercise | 264 | $0 | 1/21/2026 | View on chart |
| GH | ▲ Buy | Option Exercise | 264 | $0 | 12/21/2025 | View on chart |
| TEVA | ▼ Sell | Open Market | 77,400 | $2.3M | 12/16/2025 | View on chart |
| TEVA | ▼ Sell | Open Market | 50,000 | $1.3M | 11/26/2025 | View on chart |
| GH | ▲ Buy | Option Exercise | 264 | $0 | 11/21/2025 | View on chart |
| TEVA | ▼ Sell | Open Market | 200,000 | $4.8M | 11/6/2025 | View on chart |
| GH | ▲ Buy | Option Exercise | 3,167 | $0 | 10/21/2025 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 9,632 | — | 6/6/2025 | View on chart |
| TEVA | ▼ Sell | Open Market | 286,000 | $6.3M | 12/20/2024 | View on chart |
| TEVA | ▼ Sell | Open Market | 519,000 | $8.8M | 6/18/2024 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 21,108 | — | 6/15/2024 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 15,810 | — | 8/4/2023 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 14,479 | — | 6/14/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Guardant Health Wins Patent Ruling, Morgan Stanley Lifts Target
Guardant Health secured a favorable decision from the U.S. Patent Trial and Appeal Board, which rejected a challenge to its core duplex sequencing patent. This legal win supports the company's position in the growing liquid biopsy market. Additionally, Morgan Stanley maintained an Overweight rating and raised its price target to $200, citing strong fundamentals in the diagnostics sector.
Guardant Health Wins Patent Ruling, Morgan Stanley Lifts Target. Guardant Health secured a favorable decision from the U.S. Patent Trial and Appeal Board, which rejected a challenge to its core duplex sequencing patent. This legal win supports the company's position in the growing liquid biopsy market. Additionally, Morgan Stanley maintained an Overweight rating and raised its price target to $200, citing strong fundamentals in the diagnostics sector.